



**Citation:** Zilles JC, Obidiro O, Battogtokh G, Zimmer AR, Contri RV, Akala EO. Kojic Acid Dipalmitate-Loaded Nanoparticles for the Treatment Triple-Negative Breast Cancer. *J Nanotechnol Nanomaterials*. 2026;7(1):1–17.

## Supplementary Material




**Supplementary Figure 1.** <sup>1</sup>H-NMR spectrum of the macromonomer.




**Supplementary Figure 2.** FTIR spectrum of the macromonomer.

**Citation:** Zilles JC, Obidiro O, Battogtokh G, Zimmer AR, Contri RV, Akala EO. Kojic Acid Dipalmitate-Loaded Nanoparticles for the Treatment Triple-Negative Breast Cancer. *J Nanotechnol Nanomaterials*. 2026;7(1):1–17.




**Supplementary Figure 3.** <sup>1</sup>H-NMR spectrum of the purified crosslinker.



**Supplementary Figure 4.** FTIR spectrum of the purified crosslinker.

**Citation:** Zilles JC, Obidiro O, Battogtokh G, Zimmer AR, Contri RV, Akala EO. Kojic Acid Dipalmitate-Loaded Nanoparticles for the Treatment Triple-Negative Breast Cancer. *J Nanotechnol Nanomaterials*. 2026;7(1):1–17.



**Supplementary Figure 5.** Stability of nanoparticles at day 0 and after 90 days at room temperature storage (25°C) and refrigerated storage (4°C): particle size (A), zeta potential (B) and drug loading (C).